Get access

Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease

Authors

  • Judith Dams MSc,

    1. Department of Neurology, Philipps-University Marburg, Marburg, Germany
    Search for more papers by this author
  • Uwe Siebert MD, MPH, MSc, ScD,

    1. Department of Public Health and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria
    2. Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    3. Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Search for more papers by this author
  • Bernhard Bornschein MD, MPH,

    1. Department of Public Health and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics, and Technology, Hall in Tirol, Austria
    Search for more papers by this author
  • Jens Volkmann MD,

    1. Department of Neurology, Julius-Maximilians-University, Würzburg, Germany
    Search for more papers by this author
  • Günther Deuschl MD,

    1. Department of Neurology, Christian-Albrechts-University, Kiel, Germany
    Search for more papers by this author
  • Wolfgang H. Oertel MD,

    1. Department of Neurology, Philipps-University Marburg, Marburg, Germany
    Search for more papers by this author
  • Richard Dodel MD, MPH,

    Corresponding author
    1. Department of Neurology, Philipps-University Marburg, Marburg, Germany
    • Correspondence to: Dr. R. Dodel, Department of Neurology, Philipps-University Marburg, Baldingerstrasse, 35043 Marburg, Germany; dodel@med.uni-marburg.de

    Search for more papers by this author
  • Jens-Peter Reese PhD, MPH

    1. Department of Neurology, Philipps-University Marburg, Marburg, Germany
    Search for more papers by this author

  • Funding agencies: This study was supported by a grant from the German Ministry of Education and Research (Competence Network Parkinson syndromes; no. 01GI9901/1).

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

ABSTRACT

In addition to medical treatment, deep brain stimulation has become an alternative therapeutic option in advanced Parkinson's disease. High initial costs of surgery have to be weighted against long-term gains in health-related quality of life. The objective of this study was to assess the cost-effectiveness of deep brain stimulation compared with long-term medical treatment. We performed a cost-utility analysis using a lifetime Markov model for Parkinson's disease. Health utilities were evaluated using the EQ-5D generic health status measure. Data on effectiveness and adverse events were obtained from clinical studies, published reports, or meta-analyses. Costs were assessed from the German health care provider perspective. Both were discounted at 3% per year. Key assumptions affecting costs and health status were investigated using one-way and two-way sensitivity analyses. The lifetime incremental cost-utility ratio for deep brain stimulation was €6700 per quality-adjusted life year (QALY) and €9800 and €2500 per United Parkinson's Disease Rating Scale part II (motor experiences of daily living) and part III (motor examination) score point gained, respectively. Deep brain stimulation costs were mainly driven by the cost of surgery and of battery exchange. Health status was improved and motor complications were reduced by DBS. Sensitivity analysis revealed that battery life time was the most influential parameter, with the incremental cost-utility ratio ranging from €20,000 per QALY to deep brain stimulation dominating medical treatment. Deep brain stimulation can be considered cost-effective, offering a value-for-money profile comparable to other well accepted health care technologies. Our data support adopting and reimbursing deep brain stimulation within the German health care system. © 2013 Movement Disorder Society

Get access to the full text of this article

Ancillary